Eugene, United States
InVivo Biosystems is a leading player in the biotechnology industry, aiming to accelerate deep in-vivo insights into human biology. Specializing in CRISPR genome editing, the company creates custom genome-edited C. elegans and zebrafish models, facilitating studies on aging, developmental processes, and diseases. Their unique living platforms and technologies bridge the gap between cells and mice, enabling faster and cost-effective investigations for proof-of-principle experiments.
Founded in 2011 and headquartered in the United States, InVivo Biosystems has recently secured a significant $3.00M Venture Round investment on 03 January 2024. The investors participating in this round include Portland Seed Fund, Rogue Venture Partners, Launch Oregon, and ONAMI.
The company's mission to enable researchers to develop and deliver solutions that improve human health underscores its essential services for pharmaceutical, nutraceutical, biotechnology companies, and academic research institutions globally, propelling their research and drug development efforts forward.
With a strong focus on rapid go/no-go decision making, InVivo Biosystems is poised to advance the discovery and early-stage development of new compounds, playing a critical role in shaping the future of biotechnology and human health improvement.
